Literature DB >> 22633438

Virus chimeras for gene therapy, vaccination, and oncolysis: adenoviruses and beyond.

Johanna K Kaufmann1, Dirk M Nettelbeck.   

Abstract

Several challenges need to be addressed when developing viruses for clinical applications in gene therapy, vaccination, or viral oncolysis, including specific and efficient target cell transduction, virus delivery via the blood stream, and evasion of pre-existing immunity. With rising frequency, these goals are tackled by generating chimeric viruses containing nucleic acid fragments or proteins from two or more different viruses, thus combining different beneficial features of the parental viruses. These chimeras have boosted the development of virus-based treatment regimens for major inherited and acquired diseases, including cancer. Using adenoviruses as the paradigm and prominent examples from other virus families, we review the technological and functional advances in therapeutic virus chimera development and recent successful applications that can pave the way for future therapies.
Copyright © 2012 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22633438     DOI: 10.1016/j.molmed.2012.04.008

Source DB:  PubMed          Journal:  Trends Mol Med        ISSN: 1471-4914            Impact factor:   11.951


  30 in total

Review 1.  The sweet spot: defining virus-sialic acid interactions.

Authors:  Jennifer E Stencel-Baerenwald; Kerstin Reiss; Dirk M Reiter; Thilo Stehle; Terence S Dermody
Journal:  Nat Rev Microbiol       Date:  2014-09-29       Impact factor: 60.633

2.  Oncolytic virotherapy for gliomas: steps toward the future.

Authors:  Johanna K Kaufmann; E Antonio Chiocca
Journal:  CNS Oncol       Date:  2013-09

Review 3.  Adenovirus: the first effective in vivo gene delivery vector.

Authors:  Ronald G Crystal
Journal:  Hum Gene Ther       Date:  2014-01       Impact factor: 5.695

4.  Protective immunity elicited by measles vaccine exerts anti-tumor effects on measles virus hemagglutinin gene-modified cancer cells in a mouse model.

Authors:  Yuan Qi; Kailin Xing; Lanlin Zhang; Fangyu Zhao; Ming Yao; Aiqun Hu; Xianghua Wu
Journal:  J Cancer Res Clin Oncol       Date:  2018-08-06       Impact factor: 4.553

5.  Recent advances of oncolytic virus in cancer therapy.

Authors:  Moumita Mondal; Jingao Guo; Ping He; Dongming Zhou
Journal:  Hum Vaccin Immunother       Date:  2020-02-20       Impact factor: 3.452

6.  Oncolytic adenovirus expressing interferon alpha in a syngeneic Syrian hamster model for the treatment of pancreatic cancer.

Authors:  Christopher J LaRocca; Joohee Han; Tatyana Gavrikova; Leonard Armstrong; Amanda R Oliveira; Ryan Shanley; Selwyn M Vickers; Masato Yamamoto; Julia Davydova
Journal:  Surgery       Date:  2015-02-27       Impact factor: 3.982

7.  Production and purification of non replicative canine adenovirus type 2 derived vectors.

Authors:  Marion Szelechowski; Corinne Bergeron; Daniel Gonzalez-Dunia; Bernard Klonjkowski
Journal:  J Vis Exp       Date:  2013-12-03       Impact factor: 1.355

Review 8.  New viruses for cancer therapy: meeting clinical needs.

Authors:  Tanner S Miest; Roberto Cattaneo
Journal:  Nat Rev Microbiol       Date:  2013-12-02       Impact factor: 60.633

9.  Modeling pre-existing immunity to adenovirus in rodents: immunological requirements for successful development of a recombinant adenovirus serotype 5-based ebola vaccine.

Authors:  Jin Huk Choi; Stephen C Schafer; Lihong Zhang; Terry Juelich; Alexander N Freiberg; Maria A Croyle
Journal:  Mol Pharm       Date:  2013-08-19       Impact factor: 4.939

Review 10.  Glioma virus therapies between bench and bedside.

Authors:  Johanna K Kaufmann; E Antonio Chiocca
Journal:  Neuro Oncol       Date:  2014-01-26       Impact factor: 12.300

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.